Di Yi Cai Jing·2025-07-10 06:09Group 1 - The Trump administration plans to impose "very high" tariffs, potentially up to 200%, on imported pharmaceuticals, which could significantly increase drug prices in the U.S. [1][3] - Pharmaceutical companies have expressed strong opposition to the tariffs, warning that they may raise costs, hinder investment in the U.S., disrupt supply chains, and pose risks to patients [1][3] - The specifics of the tariff implementation are expected to be announced by the end of the month, with a grace period of one to one and a half years for companies to adjust [1][3] Group 2 - The tariffs are intended to encourage pharmaceutical companies to relocate production to the U.S., but new manufacturing facilities may take 5 to 10 years to become operational [3][4] - Major pharmaceutical companies, including Pfizer and Eli Lilly, have indicated that the threat of tariffs is already affecting their investment decisions in R&D and manufacturing in the U.S. [3][4] - The U.S. imported over $200 billion worth of pharmaceuticals in 2023, with 73% coming from Europe, primarily Ireland, Germany, and Switzerland [5] Group 3 - The majority of active pharmaceutical ingredient production has shifted to countries like China due to lower labor and production costs, leading to a significant decline in U.S. manufacturing capacity [5] - Approximately 90% of prescription drugs in the U.S. are generic medications, and imposing tariffs on these lower-margin products could drive some generic manufacturers out of the U.S. market, exacerbating shortages of essential drugs [5]